Neothetics, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“We have also direct evidence that the injection of salmeterol xinafoate reduces central abdominal bulging due to subcutaneous fat in animal models as our pre-clinical studies demonstrated that the injection of salmeterol xinafoate into the inguinal fat pad of rats produced a dose-related reduction in fat pad weight.” (Page 104) Read the full document
Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is a injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. [Source: MarketWatch]
Company Website: http://www.neothetics.com